Insmed Incorporated
INSM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $364 | $305 | $245 | $188 |
| % Growth | 19.2% | 24.4% | 30.2% | – |
| Cost of Goods Sold | $86 | $66 | $55 | $44 |
| Gross Profit | $278 | $240 | $190 | $144 |
| % Margin | 76.4% | 78.5% | 77.5% | 76.6% |
| R&D Expenses | $598 | $571 | $398 | $273 |
| G&A Expenses | $461 | $345 | $266 | $234 |
| SG&A Expenses | $461 | $345 | $266 | $234 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $97 | $34 | -$16 | $12 |
| Operating Expenses | $1,156 | $949 | $648 | $519 |
| Operating Income | -$878 | -$710 | -$457 | -$375 |
| % Margin | -241.5% | -232.5% | -186.4% | -199% |
| Other Income/Exp. Net | -$32 | -$37 | -$23 | -$61 |
| Pre-Tax Income | -$910 | -$747 | -$480 | -$436 |
| Tax Expense | $4 | $3 | $1 | -$2 |
| Net Income | -$914 | -$750 | -$482 | -$435 |
| % Margin | -251.2% | -245.6% | -196.3% | -230.6% |
| EPS | -5.57 | -5.34 | -3.91 | -3.88 |
| % Growth | -4.3% | -36.6% | -0.8% | – |
| EPS Diluted | -5.57 | -5.34 | -3.91 | -3.88 |
| Weighted Avg Shares Out | 164 | 140 | 123 | 112 |
| Weighted Avg Shares Out Dil | 164 | 140 | 123 | 112 |
| Supplemental Information | – | – | – | – |
| Interest Income | $53 | $42 | $11 | $0 |
| Interest Expense | $85 | $82 | $26 | $40 |
| Depreciation & Amortization | $11 | $11 | $10 | $14 |
| EBITDA | -$819 | -$660 | -$447 | -$384 |
| % Margin | -225.1% | -216.3% | -182.3% | -203.6% |